Premium
Dendritic cell immunotherapy
Author(s) -
Sabado Rachel Lubong,
Bhardwaj Nina
Publication year - 2013
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12125
Subject(s) - immunotherapy , immunogenicity , immune system , dendritic cell , clinical trial , immunology , medicine , tumor microenvironment , peripheral tolerance , in vivo , immune tolerance , food and drug administration , cancer research , biology , pharmacology , microbiology and biotechnology
The U.S. Food and Drug Administration's approval of the first cell‐based immunotherapy has rejuvenated interest in the field. Early clinical trials have established the ability of dendritic cell (DC) immunotherapy to exploit a patient's own immune system to induce antitumor immune responses. However, suboptimal conditions for generating potent immunostimulatory DCs, in addition to the suppression mediated by the tumor microenvironment, have contributed to limited clinical success in vivo . Therefore, combining DC vaccines with new approaches that enhance immunogenicity and overcome the regulatory mechanisms underlying peripheral tolerance may be key to achieving effective, durable, antitumor immune responses that translate to better clinical outcomes.